DOD Amyotrophic Lateral Sclerosis Research Program (ALSRP) – application
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 24th, September 2026
External Deadline: Wednesday 30th, September 2026
Description
Clinical Outcomes and Biomarkers Award
The FY26 ALSRP COBA supports the development and/or validation of clinical outcomes and
biomarkers to enrich clinical trials in ALS. Projects can be relevant to a specific therapy, a class
of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not
have to broadly apply to all patients. Biomarkers should be specific for ALS, rather than
generic. The FY26 ALSRP is particularly interested in studies that compare ALS-specific
biomarkers to its mimics.
Pilot Clinical Trial Award
The FY26 ALSRP Pilot Clinical Trial Award supports the rapid implementation of clinical trials
with the potential to have a significant impact on the treatment or symptom management of
ALS. Proposed research projects must include clinical trials that address more than just safety
of the intervention. Projects should also be designed to assess therapeutic efficacy, biological
effects, and/or clinical outcomes, and may range from phase 1 to small-scale phase 2 trials.
Therapeutic Development Award
The FY26 ALSRP Therapeutic Development Award supports research ranging from preclinical
validation of therapeutic leads through FDA IND-enabling studies. The proposed studies are
expected to be empirical in nature and product-driven. Applicants with limited ALS experience
are strongly encouraged to include collaborators with substantial experience in the relevant ALS
model systems, endpoints and pathophysiology.
Therapeutic Idea Award
The FY26 ALSRP Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain
ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or therapy discovery. The studies
supported by this award mechanism are expected to be hypothesis-driven and generate
preliminary data for future avenues of therapeutic investigation.
To view the ALSRP funding opportunity announcements and submit a pre-application, visit https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=707101
Pre-Application Due: June 24, 2026
Application Due: September 30, 2026